# BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

> **NCT01672671** · PHASE2 · COMPLETED · sponsor: **Russian Academy of Medical Sciences** · enrollment: 41 (actual)

## Conditions studied

- Early Triple Negative Breast Cancer

## Interventions

- **DRUG:** Doxorubicin, Paclitaxel, Cisplatin

## Key facts

- **NCT ID:** NCT01672671
- **Lead sponsor:** Russian Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01672671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01672671, "BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01672671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*